Financial & Business News

Here is how Adaptive Biotechnologies (ADPT) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Here is how Byd Co., Ltd. (BYDDY) and General Motors (GM) have performed compared to their sector so far this year.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

AEP continues to benefit from its systematic investment plan and renewable portfolio expansion initiatives.

Galp Energia drops its plans for the Aurora lithium refinery project following its failure to secure a new partner to replace Northvolt AB.

Hims & Hers achieved a 44% YoY increase in Q3 2024, surpassing 2 million active users. Q3 2024 revenue rose 77% YoY to $401.6M, with $392.6M from online channels (+79% YoY). GLP-1 patient retention at 12 weeks reached 70%, outperforming the industry average of less than 42%.

Axsome's AXS-12 met its primary endpoint in a Phase 3 study, significantly reducing cataplexy attacks in narcolepsy patients, positioning it for an NDA submission. The narcolepsy market is substantial, with current treatments having issues like tolerability and efficacy, which AXS-12 aims to address effectively. Financially, Axsome has a market cap of $4.83bn, strong revenue growth, but a net loss, indicating a cash runway of four to five quarters.

Cancer treatment has long been dominated by traditional approaches such as surgery, radiation, and chemotherapy. But in recent years, a wave of innovation has emerged, driven by the promise of immunotherapies that harness the body's own immune system to fight cancer.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?